Drug Trial Radar · NCT06383052
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Last checked: Nov 20, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Actual
Start
Apr 26, 2024
Primary completion
Jun 30, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Norroy Bioscience Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
177Lu-NYM032 injectionDrug
Radionuclide 177Lu will be used as a therapeutic nuclide for this study. The precursor of NYM032 will be labeled with 177Lu to form the chelation product, 177Lu-NYM032 injection which will be used in this study as a intravenous injection dose of 177Lu-NYM032. The radiation dose is chosen within the range of 50-200 mCi for an individual patient at every dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Dose Limiting Toxicity (DLT)Time frame: 28 days
- Maximum Tolerated Dose (MTD)Time frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affliated Hospital of Jiangnan University
Wuxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.